The Switch Study: Switching from BHI 30 Novolet? to BIAsp 30 Flexpen?: ‘Clinical Observations from the Netherlands’. Treatment Satisfaction when Switching from BHI 30 NovoLet? to BIAsp 30 FlexPen?

摘要

Aim: An open label non-randomized observational study was performed to observe and investigate the process of switching from premixed human insulin 30/70 (BHI 30) in NovoLet? to biphasic insulin aspart 30/70 (BIAsp 30) in FlexPen? in an outpatient setting; in terms of insulin dose, efficacy, hypoglycemic episodes, quality of life (WHO-5) and treatment satisfaction (ITSQ; Insulin Treatment Satisfaction Questionnaire). Methods: Type 2 diabetic patients (aged ≥ 18 yrs) treated with BHI30 in NovoLet? who were switched to BIAsp 30 in FlexPen? were included in an open-labeled, multicenter, non-randomized, observational study. At baseline and 8 ± 2 weeks after switching to BIAsp 30 FlexPen? HbA1c, insulin dose, number of hypoglycemic events and quality of life were measured. Results: A total of 196 patients (54.3% female, aged 64.8 ± 12 years) with type 2 diabetes completed the study. Total insulin dose remained stable 52.8 ± 24.9 units at baseline vs. 52.0 ± 25.6 units after 8 weeks of treatment, as did HbA1c, 7.7 ± 1.4% at baseline vs. 7.7% ± 1.4%. No weight change was reported (81.6 ± 16.6 kg vs. 81.5 ± 16.7 kg). With BIAsp 30, a significantly lower number of total hypoglycemic episodes were reported (127 compared to 188 with BHI 30, p ? device and 89.1% wanted to continue treatment with FlexPen?. The WHO-5 scores after the final visit showed no general quality of life problems with average scores between 2.7 and 3.3. Conclusion: The results of this study provided evidence that switching from BHI 30 NovoLet? to BIAsp 30 FlexPen? can be done easily on a unit by unit basis in daily practice in type 2 diabetic patients. After 8 weeks of treatment with BIAsp 30 there was a significant decrease in hypoglycemic episodes accompanied by a significant increase in treatment satisfaction.